J&J Acquires Rights to IBD Experimental Drug from Vedanta

J&J Acquires Rights to IBD Experimental Drug from Vedanta
Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has signed a license agreement with Vedanta Biosciences to acquire the rights for an investigational therapeutic alternative for the treatment of inflammatory bowel diseases (IBD), as announced by the companies in a recent press release. The novel IBD drug has been developed by Vedanta and

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *